PBM Vertical Integration Impact Under The Microscope At Senate Hearing
Witnesses Were Divided On The Severity Of Vertical Integration Impact In US
Executive Summary
A US Senate Finance Committee has heard divided opinions on the impact of vertical integration among pharmacy benefit managers, with one witness maintaining it may have positive competitive consequences while another condemned the practice outright.
You may also be interested in...
Bipartisan Senate Finance Framework Takes ‘Measured’ Aim At PBMs
Framework from Sens. Wyden and Crapo, looks like it would change, but not eliminate, the rebate system and gets an initial thumbs up from both the brand and generic drug lobbies.
PBM Transparency Act Advances In Senate And It’s A Far Cry From The Rebate Rule
Bill aims to lower patient costs in part by engaging the US Federal Trade Commission to shed light on pharmacy benefit manager transactions with health plans, manufacturers and pharmacies.
Congressional Pressure Mounts On PBMs, But Skepticism Remains About Near-Term Action
Attention on PBMs with minimal risk of policy change may represent the best of both worlds for pharma, which benefits from another part of the industry taking the heat on drug prices but could stand to lose out financially depending on the PBM reform approaches taken.